Plasma concentration of pyridostigmine and effects in myastenia gravis.
The relation between the plasma concentration of pyridostigmine and its effects was studied in 5 patients with myasthenia gravis. In 4 patients with typical electromyographic decrement in the adductor pollicis, there was a positive correlation between the concentration  of pyridostigmine in plasma and the effect on neuromuscular transmission. The plasma concentration of pyridostigmine required to restore transmission to normal (as calculated from the regression line relating plasma concentration to neuromuscular function) varied over a 5-fold range, reflecting the variable severity of the disease. In another myasthenic patient with purely ocular symptoms, there was a significant correlation between the plasma concentration of the drug and the diameter of the palpebral fissure. It is suggested that the routine measurement of the plasma concentration of pyridostigmine may be of value in the management of myasthenia gravis. A method to calculate the optimal daily dose of pyridostigmine in individual myasthenic patients is described.
D001763:Blepharoptosis / Q000188:drug therapy; D004576:Electromyography; D006801:Humans; D009157:Myasthenia Gravis / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D009469:Neuromuscular Junction / Q000187:drug effects / Q000503:physiopathology; D011729:Pyridostigmine Bromide / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use; D009435:Synaptic Transmission / Q000187:drug effects
D011729:Pyridostigmine Bromide